We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CRISPR Therapeutics AG | NASDAQ:CRSP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.57 | -1.03% | 54.90 | 54.35 | 54.95 | 55.77 | 54.30 | 55.00 | 1,118,082 | 00:41:32 |
Title: Development of an In Vivo Non-Viral Ocular Editing Platform and Application to Potential Treatments for GlaucomaSession Type: In-Person Oral Presentation Session Title: Ophthalmic and Auditory: Delivery InnovationsAbstract Number: 87Location: Room 318 – 323Session Date and Time: Wednesday, May 8, 2024, 1:30 p.m. – 3:15 p.m. ET
Abstracts will be released to the public on April 22, 2024, at 4:30 p.m. ET at https://annualmeeting.asgct.org/. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 8, 2024. A copy of the presentation will be available at www.crisprtx.com once the presentation concludes.
About CRISPR Therapeutics Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company with a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular and rare diseases. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. To learn more, visit www.crisprtx.com.
Investor Contact: Susan Kim +1-617-307-7503 susan.kim@crisprtx.com
Media Contact: Rachel Eides +1-617-315-4493 rachel.eides@crisprtx.com
1 Year CRISPR Therapeutics Chart |
1 Month CRISPR Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions